Tumor-Infiltrating Lymphocytes (TILs) in Epithelial Ovarian Cancer: Heterogeneity, Prognostic Impact, and Relationship with Immune Checkpoints.
epithelial ovarian cancer (EOC)
high-grade serous ovarian cancer (HGSOC)
immune checkpoint inhibitors
peritoneum
tumor microenvironment
tumor-infiltrating lymphocytes (TILs)
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
29 Oct 2022
29 Oct 2022
Historique:
received:
06
09
2022
revised:
24
10
2022
accepted:
26
10
2022
entrez:
11
11
2022
pubmed:
12
11
2022
medline:
12
11
2022
Statut:
epublish
Résumé
Epithelial ovarian cancers (EOC) are often diagnosed at an advanced stage with carcinomatosis and a poor prognosis. First-line treatment is based on a chemotherapy regimen combining a platinum-based drug and a taxane-based drug along with surgery. More than half of the patients will have concern about a recurrence. To improve the outcomes, new therapeutics are needed, and diverse strategies, such as immunotherapy, are currently being tested in EOC. To better understand the global immune contexture in EOC, several studies have been performed to decipher the landscape of tumor-infiltrating lymphocytes (TILs). CD8+ TILs are usually considered effective antitumor immune effectors that immune checkpoint inhibitors can potentially activate to reject tumor cells. To synthesize the knowledge of TILs in EOC, we conducted a review of studies published in MEDLINE or EMBASE in the last 10 years according to the PRISMA guidelines. The description and role of TILs in EOC prognosis are reviewed from the published data. The links between TILs, DNA repair deficiency, and ICs have been studied. Finally, this review describes the role of TILs in future immunotherapy for EOC.
Identifiants
pubmed: 36358750
pii: cancers14215332
doi: 10.3390/cancers14215332
pmc: PMC9656626
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
N Engl J Med. 2010 Sep 2;363(10):943-53
pubmed: 20818904
Am Soc Clin Oncol Educ Book. 2020 May;40:1-13
pubmed: 32412818
Cancer Genomics Proteomics. 2020 Sep-Oct;17(5):529-541
pubmed: 32859631
Cancers (Basel). 2021 Sep 30;13(19):
pubmed: 34638409
Oncol Lett. 2019 May;17(5):4557-4565
pubmed: 30944645
J Ovarian Res. 2019 Jun 17;12(1):56
pubmed: 31208449
BMC Cancer. 2017 Sep 20;17(1):657
pubmed: 28931370
Lancet. 2015 Jul 18;386(9990):249-57
pubmed: 26002111
Sci Rep. 2021 Mar 18;11(1):6400
pubmed: 33737722
Oncotarget. 2016 Mar 22;7(12):13587-98
pubmed: 26871470
J Immunother Cancer. 2020 May;8(1):
pubmed: 32461346
Int J Gynecol Cancer. 2020 Nov;30(11):1657-1664
pubmed: 33028623
Life Sci. 2021 Jul 15;277:119461
pubmed: 33811900
Cancers (Basel). 2020 Feb 27;12(3):
pubmed: 32120793
Clin Exp Immunol. 2021 Oct;206(1):36-46
pubmed: 34195995
Int J Gynecol Pathol. 2013 May;32(3):269-76
pubmed: 23518910
Medicines (Basel). 2018 Feb 01;5(1):
pubmed: 29389895
J Immunother Cancer. 2014 Nov 18;2(1):38
pubmed: 25436113
Int J Gynecol Pathol. 2020 Nov;39(6):558-566
pubmed: 31851060
Oncoimmunology. 2021 Jun 6;10(1):1935104
pubmed: 34123576
Int Immunopharmacol. 2017 Nov;52:7-14
pubmed: 28846888
Oncotarget. 2016 Jan 12;7(2):1486-99
pubmed: 26625204
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Gynecol Oncol. 2018 Oct;151(1):10-17
pubmed: 30078505
N Engl J Med. 2003 Jan 16;348(3):203-13
pubmed: 12529460
Clin Cancer Res. 2016 Jun 15;22(12):3025-36
pubmed: 27306793
PeerJ. 2020 Nov 23;8:e10255
pubmed: 33282553
Neoplasia. 2018 Mar;20(3):280-288
pubmed: 29466768
N Engl J Med. 2018 Jan 18;378(3):230-240
pubmed: 29342393
Oncoimmunology. 2014 Jan 10;3:e27668
pubmed: 25101220
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Oncoimmunology. 2019 Mar 28;8(6):e1593811
pubmed: 31069161
J Natl Compr Canc Netw. 2019 Aug 1;17(8):896-909
pubmed: 31390583
Clin Cancer Res. 2014 Jul 15;20(14):3818-29
pubmed: 24916698
Lancet. 2019 Mar 23;393(10177):1240-1253
pubmed: 30910306
Reprod Sci. 2013 Jul;20(7):828-37
pubmed: 23239818
Lancet Oncol. 2019 Aug;20(8):e417-e433
pubmed: 31364594
J Immunother Cancer. 2019 Oct 26;7(1):278
pubmed: 31655605
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Cancers (Basel). 2019 Aug 26;11(9):
pubmed: 31455033
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
APMIS. 2021 May;129(5):254-264
pubmed: 33455015
ESMO Open. 2021 Apr;6(2):100098
pubmed: 33819750
Ginekol Pol. 2021;92(5):344-351
pubmed: 33914317
PLoS One. 2013 Nov 14;8(11):e80063
pubmed: 24244610
Gynecol Oncol. 2012 Feb;124(2):192-8
pubmed: 22040834
BMC Cancer. 2013 Sep 17;13:422
pubmed: 24044611
Adv Anat Pathol. 2017 Nov;24(6):311-335
pubmed: 28777143
Adv Anat Pathol. 2017 Sep;24(5):235-251
pubmed: 28777142
Gynecol Oncol. 2016 May;141(2):293-302
pubmed: 26972336
J Egypt Natl Canc Inst. 2021 Jul 9;33(1):16
pubmed: 34241710
Cancer Res. 2016 Oct 1;76(19):5597-5601
pubmed: 27634765
Oncologist. 2021 Oct;26(10):e1786-e1799
pubmed: 34196068
Lancet. 2001 Jun 2;357(9270):1777-89
pubmed: 11403834
Int Immunol. 2020 May 30;32(6):397-405
pubmed: 32009163
Cancers (Basel). 2021 Jul 30;13(15):
pubmed: 34359755
Nat Genet. 2020 Jun;52(6):582-593
pubmed: 32483290
Sci Transl Med. 2021 Jan 20;13(577):
pubmed: 33472952
JAMA Netw Open. 2020 Aug 3;3(8):e2013940
pubmed: 32840622
Int J Gynecol Cancer. 2019 Feb;29(2):353-356
pubmed: 30683759
Gynecol Oncol. 2018 Apr;149(1):146-154
pubmed: 29496294
Am J Surg Pathol. 2020 Aug;44(8):1050-1060
pubmed: 32384321
Sci Rep. 2019 Nov 26;9(1):17589
pubmed: 31772388
Sci Transl Med. 2013 Dec 4;5(214):214ra169
pubmed: 24307693
J Ovarian Res. 2016 Apr 06;9:21
pubmed: 27048364
Blood. 2009 Aug 6;114(6):1141-9
pubmed: 19470694
Gynecol Oncol. 2016 Oct;143(1):120-127
pubmed: 27470997
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Nat Rev Cancer. 2005 May;5(5):397-405
pubmed: 15864281
J Clin Oncol. 2020 Oct 20;38(30):3528-3537
pubmed: 32749942
Ann Oncol. 2017 Mar 1;28(3):651-657
pubmed: 27864219
N Engl J Med. 2019 Dec 19;381(25):2416-2428
pubmed: 31851799
Clin Cancer Res. 2021 Jul 15;27(14):4089-4100
pubmed: 33963000
Pathol Oncol Res. 2012 Apr;18(2):509-18
pubmed: 22161157
Clin Cancer Res. 2019 Aug 1;25(15):4820-4831
pubmed: 31076549
Cancers (Basel). 2021 Apr 08;13(8):
pubmed: 33917869
PeerJ. 2020 Nov 24;8:e10414
pubmed: 33282564
Am J Pathol. 2016 May;186(5):1103-13
pubmed: 26993207
Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43
pubmed: 16344461
N Engl J Med. 2011 Dec 29;365(26):2484-96
pubmed: 22204725
Cancer Immunol Immunother. 2010 Jun;59(6):909-19
pubmed: 20087581
Nat Med. 2004 Sep;10(9):942-9
pubmed: 15322536
Clin Cancer Res. 2016 Jun 15;22(12):3005-15
pubmed: 26763251
Cancer Immunol Res. 2015 Mar;3(3):245-53
pubmed: 25480168
Syst Rev. 2015 Jan 01;4:1
pubmed: 25554246
Cancer Immun. 2013;13:1
pubmed: 23390372
JAMA Oncol. 2017 Dec 1;3(12):e173290
pubmed: 29049607
Cell Rep. 2021 May 25;35(8):109165
pubmed: 34038734
Mol Cancer Res. 2019 Dec;17(12):2537-2548
pubmed: 31537619
Cancer Immunol Immunother. 2021 Feb;70(2):519-531
pubmed: 32852603
Nat Commun. 2018 Mar 15;9(1):1092
pubmed: 29545564
Oncol Lett. 2017 Jan;13(1):159-166
pubmed: 28123537
Eur J Obstet Gynecol Reprod Biol. 2017 Aug;215:55-61
pubmed: 28601728
Clin Cancer Res. 2017 Dec 15;23(24):7621-7632
pubmed: 28972047
Nat Rev Cancer. 2012 Mar 15;12(4):298-306
pubmed: 22419253
Cancer Immunol Immunother. 2009 Mar;58(3):449-59
pubmed: 18791714
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3360-5
pubmed: 17360651
Cancer Immunol Res. 2015 Aug;3(8):926-35
pubmed: 25957117
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
Lancet Oncol. 2020 Jul;21(7):969-977
pubmed: 32615110
Virchows Arch. 2020 Oct;477(4):535-544
pubmed: 32179982
Virchows Arch. 2020 Jul;477(1):83-91
pubmed: 31980961
Nat Rev Immunol. 2020 Mar;20(3):173-185
pubmed: 31676858
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Nat Commun. 2018 Sep 25;9(1):3917
pubmed: 30254278
Ther Adv Med Oncol. 2021 Apr 22;13:17588359211008399
pubmed: 33995591
Int J Gynecol Cancer. 2020 Jun;30(6):888-892
pubmed: 32205449
Cancer Immunol Immunother. 2019 Nov;68(11):1747-1757
pubmed: 31602489
Eur J Immunol. 2004 Feb;34(2):336-44
pubmed: 14768038
Br J Cancer. 2019 Feb;120(4):424-434
pubmed: 30718808
Clin Cancer Res. 2014 Jan 15;20(2):434-44
pubmed: 24190978
PLoS One. 2014 Nov 03;9(11):e111757
pubmed: 25365237
Oncoimmunology. 2015 Apr 14;4(11):e1030561
pubmed: 26451311
Hum Pathol. 2018 Apr;74:135-147
pubmed: 29288043
Front Genet. 2021 Feb 10;12:616073
pubmed: 33679883
Cancer Immunol Immunother. 2015 Mar;64(3):337-47
pubmed: 25416072
Oncoimmunology. 2020 Apr 30;9(1):1760067
pubmed: 32391193
Gynecol Oncol. 2019 May;153(2):217-222
pubmed: 30803719
Gynecol Oncol. 2020 Sep;158(3):608-613
pubmed: 32518012
Cancer Med. 2021 Jun;10(12):3905-3918
pubmed: 33955198
Ann Oncol. 2016 Apr;27 Suppl 1:i11-i15
pubmed: 27141063
Cancer Biol Ther. 2011 Aug 15;12(4):357-66
pubmed: 21785264
Nat Commun. 2013;4:2612
pubmed: 24113773
Gynecol Oncol. 2021 Sep;162(3):686-693
pubmed: 34275654
Cancer Immunol Immunother. 2019 Sep;68(9):1515-1526
pubmed: 31515669
Gynecol Oncol. 2010 Sep;118(3):228-36
pubmed: 20541243
Mol Omics. 2018 Oct 8;14(5):341-351
pubmed: 30129640
J Leukoc Biol. 2020 Jun;107(6):1081-1095
pubmed: 31833593
Int J Mol Sci. 2021 May 27;22(11):
pubmed: 34071938
PLoS One. 2009 Jul 29;4(7):e6412
pubmed: 19641607
Oncotarget. 2020 Jul 07;11(27):2669-2683
pubmed: 32676168
Mol Ther Nucleic Acids. 2020 Dec 10;23:536-551
pubmed: 33510942
Cancer Biol Ther. 2011 Aug 15;12(4):367-77
pubmed: 21785280
Gynecol Oncol. 2010 Mar;116(3):556-62
pubmed: 20006900
PLoS One. 2010 Dec 22;5(12):e15625
pubmed: 21203522
Clin Cancer Res. 2012 Jun 15;18(12):3281-92
pubmed: 22553348
J Oncol. 2020 Feb 21;2020:8797683
pubmed: 32148497